A Trial Of Embryonic Stem Cell Implant On High-Risk Patients With Type 1 Diabetes By The ViaCyte
An attempt to cure type 1 diabetes (T1D) was started by implantation of embryonic stem cell in the forearm of the patient, developed by ViaCyte, San Diego, California, United States. They have implanted embryonic stem cell into two patients who are at high risk of type 1 diabetes (T1D). The implanted stem cells take about three months to mature into islet cells to secrete insulin.
The trials of a smaller implant were already done on 19 individuals and they are going to conduct a similar procedure on 40 more individuals later this year. The preliminary results of this procedure will be known in the first of 2018.
The researchers are hoping that this procedure can help patients with type 1 diabetes (T1D) in managing the high blood sugar (glucose) levels. The researchers call this procedure as "functional cure" therapy. This procedure can not cure the cause of the disease. This procedure is replacing the missing islet cells for secretion of insulin.
This procedure will improve the lives of a number of patients with type 1 diabetes (T1D) as pancreas was unable to produce enough insulin to manage their high blood sugar (glucose) levels. But the people who have undergone embryonic stem cell need to take immunosuppressive drugs to protect the implanted cells from the immune system. The investigator of the trial was James Shapiro MD, Ph.D., Professor of Surgery, Medicine and Surgical Oncology, the University of Alberta, Edmonton, Alberta, Canada.
The MonoPepT1De Trial Shows A Slow Down In The Development Of Type 1 Diabetes With A Retrained Immune System
Even though an individual was diagnosed with type 1 diabetes (T1D), Prof. Mark Peakman says that between 15 and 20 percent of beta cells in the pancreas can secrete insulin. If the remaining beta cells were protected, the type 1 diabetes (T1D) patient will require less insulin to control the high blood sugar (glucose) levels. So, the researchers wanted to protect the remaining cells from the attack of the immune system with a retrained immune system.
The MonoPepT1De trial with the support of JDRF and Diabetes UK by the researchers from the Cardiff University and King's College London (KCL) shows the possibilities to "retrain" the immune system of the patients with type 1 diabetes. Then, the immune system can slow down the advancement of type 1 diabetes (T1D) and protect the remaining beta cells in the pancreas.
The researchers have found that an injection of the "small fragments" of protein molecules into a patient with type 1 diabetes (T1D) had a marked improvement in the behavior of the immune system. The immune system has prevented a further attack on insulin-producing beta cells in the pancreas.
There is no cure to type 1 diabetes (T1D) but the current trial shows that the researchers are "heading in the right direction" for the treatment of type 1 diabetes (T1D). The researchers used peptide technology in the MonoPepT1De trial, which is a safe procedure currently. They also say that the peptide technology can show a marked improvement on the immune system.
With the success of the MonoPepT1De trial, the researchers are planning to conduct the MultipepT1De (next-generation immunotherapy) Phase 1B study. UCB Biopharma, a Belgian Biopharmaceutical company has received an exclusive license from the King's College London for the MultipepT1De and MonopepT1De.
The lead investigator of the trial was Prof. Mark Peakman, MBBS, BSc, MSc, Ph.D., FRCPath, the King's College London and chief investigator of the trial was Prof. Colin Dayan, from Cardiff University. The trial was published on August 9, 2017, in the journal Science Translational Medicine. Title of the article was "Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.